NO20093039L - Indolizineddiksyrederivater som CRTH2 antagonister - Google Patents

Indolizineddiksyrederivater som CRTH2 antagonister

Info

Publication number: NO20093039L
Authority: NO; Norway
Prior art keywords: cyano; acetic acid; methylindolizin; chloro; indolizinedacetic
Prior art date: 2007-03-21

Application number

NO20093039A

Other languages

English (en)

Norwegian (no)

Inventor

George Hynd

Harry Finch

Michael Colin Cramp

Rosa Arienzo

Yann Griffon

Trevor Keith Harrison

John Gary Montana

Nicholas Charles Ray

Paul Matthew Blaney

David Middlemiss

Original Assignee

Argenta Oral Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-21

Filing date

2009-09-22

Publication date

2009-11-17

2009-09-22 Application filed by Argenta Oral Therapeutics Ltd filed Critical Argenta Oral Therapeutics Ltd

2009-11-17 Publication of NO20093039L publication Critical patent/NO20093039L/no

Links

102000009389 Prostaglandin D receptors Human genes 0.000 title abstract 2
108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 2
239000002253 acid Substances 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
QNZMWMQQEIPILF-UHFFFAOYSA-N 2-[1-(3-chloro-4-ethylsulfonylphenyl)sulfanyl-7-cyano-2-methylindolizin-3-yl]acetic acid Chemical compound C1=C(Cl)C(S(=O)(=O)CC)=CC=C1SC1=C2C=C(C#N)C=CN2C(CC(O)=O)=C1C QNZMWMQQEIPILF-UHFFFAOYSA-N 0.000 abstract 1
CSFZMLYQSYYPTP-UHFFFAOYSA-N 2-[1-(3-chloro-4-morpholin-4-ylsulfonylphenyl)sulfanyl-7-cyano-2-methylindolizin-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)N2C=CC(C#N)=CC2=C1SC(C=C1Cl)=CC=C1S(=O)(=O)N1CCOCC1 CSFZMLYQSYYPTP-UHFFFAOYSA-N 0.000 abstract 1
UZUOVNZGLIQZCG-UHFFFAOYSA-N 2-[1-[(3-chloro-4-ethylsulfonylphenyl)methyl]-7-cyano-2-methylindolizin-3-yl]acetic acid Chemical compound C1=C(Cl)C(S(=O)(=O)CC)=CC=C1CC1=C2C=C(C#N)C=CN2C(CC(O)=O)=C1C UZUOVNZGLIQZCG-UHFFFAOYSA-N 0.000 abstract 1
DAFHEJQMJQJFKM-UHFFFAOYSA-N 2-[1-[(3-chloro-4-morpholin-4-ylsulfonylphenyl)methyl]-7-cyano-2-methylindolizin-3-yl]acetic acid Chemical compound C=12C=C(C#N)C=CN2C(CC(O)=O)=C(C)C=1CC(C=C1Cl)=CC=C1S(=O)(=O)N1CCOCC1 DAFHEJQMJQJFKM-UHFFFAOYSA-N 0.000 abstract 1
QUFADXMDDCWCOX-UHFFFAOYSA-N 2-[7-cyano-1-[(6-fluoroquinolin-2-yl)methyl]-2-methylindolizin-3-yl]acetic acid Chemical compound C1=C(C#N)C=CN2C(CC(O)=O)=C(C)C(CC=3N=C4C=CC(F)=CC4=CC=3)=C21 QUFADXMDDCWCOX-UHFFFAOYSA-N 0.000 abstract 1
BUOKMTLZXJTRSP-UHFFFAOYSA-N 2-[7-cyano-2-methyl-1-[(4-morpholin-4-ylsulfonylphenyl)methyl]indolizin-3-yl]acetic acid Chemical compound C=12C=C(C#N)C=CN2C(CC(O)=O)=C(C)C=1CC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 BUOKMTLZXJTRSP-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20093039A 2007-03-21 2009-09-22 Indolizineddiksyrederivater som CRTH2 antagonister NO20093039L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/GB2007/000996 WO2008113965A1 (en)	2007-03-21	2007-03-21	Indolizine acetic acid derivatives as crth2 antagonists

Publications (1)

Publication Number	Publication Date
NO20093039L true NO20093039L (no)	2009-11-17

Family

ID=38436764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20093039A NO20093039L (no)	2007-03-21	2009-09-22	Indolizineddiksyrederivater som CRTH2 antagonister

Country Status (12)

Country	Link
US (1)	US20100137300A1 (pt)
EP (1)	EP2136804A1 (pt)
JP (1)	JP2010522149A (pt)
CN (1)	CN101678009A (pt)
AU (1)	AU2007349641A1 (pt)
BR (1)	BRPI0721477A2 (pt)
CA (1)	CA2681409A1 (pt)
EA (1)	EA200970875A1 (pt)
IL (1)	IL201090A0 (pt)
MX (1)	MX2009010068A (pt)
NO (1)	NO20093039L (pt)
WO (1)	WO2008113965A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0719485D0 (en) *	2007-10-05	2007-11-14	Argenta Discovery Ltd	Compounds
DK2229358T3 (da)	2007-12-14	2011-07-04	Pulmagen Therapeutics Asthma Ltd	Indoler og deres terapeutiske anvendelse
AR080703A1 (es)	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en)	2011-04-14	2016-09-05	Actelion Pharmaceuticals Ltd	7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SG11201402796SA (en)	2011-12-16	2014-06-27	Atopix Therapeutics Ltd	Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
PE20161177A1 (es)	2014-03-17	2016-11-18	Actelion Pharmaceuticals Ltd	Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES421284A1 (es) *	1973-12-07	1976-04-16	Farmasimes S A	Procedimiento para la preparacion de derivados de acidos pirrocolinaceticos.
SE0201635D0 (sv) *	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
WO2005040112A1 (en) *	2003-10-14	2005-05-06	Oxagen Limited	Compounds with pgd2 antagonist activity
GB0324763D0 (en) *	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
GB2407318A (en) *	2003-10-23	2005-04-27	Oxagen Ltd	Substituted Indol-3-yl acetic acid derivatives
GB0512944D0 (en) *	2005-06-24	2005-08-03	Argenta Discovery Ltd	Indolizine compounds
GB0518783D0 (en) *	2005-09-14	2005-10-26	Argenta Discovery Ltd	Indolizine compounds

2007
- 2007-03-21 EP EP07732088A patent/EP2136804A1/en not_active Withdrawn
- 2007-03-21 BR BRPI0721477-4A patent/BRPI0721477A2/pt not_active IP Right Cessation
- 2007-03-21 CN CN200780052278A patent/CN101678009A/zh active Pending
- 2007-03-21 EA EA200970875A patent/EA200970875A1/ru unknown
- 2007-03-21 JP JP2009554075A patent/JP2010522149A/ja not_active Withdrawn
- 2007-03-21 AU AU2007349641A patent/AU2007349641A1/en not_active Abandoned
- 2007-03-21 WO PCT/GB2007/000996 patent/WO2008113965A1/en not_active Ceased
- 2007-03-21 CA CA002681409A patent/CA2681409A1/en not_active Abandoned
- 2007-03-21 MX MX2009010068A patent/MX2009010068A/es not_active Application Discontinuation
- 2007-03-21 US US12/530,929 patent/US20100137300A1/en not_active Abandoned
2009
- 2009-09-21 IL IL201090A patent/IL201090A0/en unknown
- 2009-09-22 NO NO20093039A patent/NO20093039L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2008113965A1 (en)	2008-09-25
EP2136804A1 (en)	2009-12-30
AU2007349641A1 (en)	2008-09-25
EA200970875A1 (ru)	2010-04-30
BRPI0721477A2 (pt)	2013-01-15
IL201090A0 (en)	2010-05-17
CA2681409A1 (en)	2008-09-25
JP2010522149A (ja)	2010-07-01
MX2009010068A (es)	2010-02-24
CN101678009A (zh)	2010-03-24
US20100137300A1 (en)	2010-06-03

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20093039L (no)	2009-11-17	Indolizineddiksyrederivater som CRTH2 antagonister
NO20080408L (no)	2008-03-25	Azaindazolforbindelser og anvendelse derav
NO20084489L (no)	2008-12-19	Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
WO2009076141A8 (en)	2010-07-15	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JO3021B1 (ar)	2016-09-05	احادي هيدرات 4-[ 4-{[4- كلورو - 3- (ثلاثي فلورو ميثيل) فينيل ] كربامويل} امينو] -3- فلورو فينوكسي] -n- ميثيل بيريدين -2- كربوكساميد
NO20070855L (no)	2007-03-19	Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20072352L (no)	2007-05-31	Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
DK2324008T3 (da)	2012-07-23	Diarylpyrazol som protein kinase inhibitorer
ATE469897T1 (de)	2010-06-15	Indazolcarbonsäureamidverbindungen
NO20073628L (no)	2007-07-16	Pyridoner som er nyttige som inhibitorer av kinaser
NO20084540L (no)	2008-10-28	Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren
EA200970946A1 (ru)	2010-04-30	Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха
GB0400895D0 (en)	2004-02-18	Chemical compounds
NO20071619L (no)	2007-04-25	Fremgangsmate for fremstilling av indazol forbindelse
NZ604379A (en)	2015-01-30	Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
NO20070293L (no)	2007-03-15	Aryl-substituerte piperazinderivater
BR112014009910A2 (pt)	2017-04-25	formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
NO20080445L (no)	2008-01-23	Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
NO20092694L (no)	2009-07-17	CRTH2 antagonister
TW200616953A (en)	2006-06-01	Indole, indazole or indoline derivatives
WO2009038385A3 (en)	2009-06-18	Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
NO20081082L (no)	2008-02-29	Nye piperidinderivater som kjemokinreseptorformulatorer som er nyttige for behandling av respiratoriske sykdommer
TN2011000457A1 (en)	2013-03-27	Method or system using biomarkers for the monitoring of a treatment
DE602006017574D1 (de)	2010-11-25	Als protein-kinase-inhibitoren nutzbare benzimidazole
HUP0401527A2 (en)	2006-01-30	New indole and benzimidazole carboxylic acid amide derivatives, process for producing them, their use and pharmaceutical compositions containing them